---
{"dg-publish":true,"permalink":"/USMLE/Blood/Primary myelofibrosis/"}
---

Description: any MPN leading to <span style="background:rgba(240, 200, 0, 0.2)">bone marrow fibrosis, extramedullary hematopoiesis, and [[USMLE/Blood/Splenomegaly\|splenomegaly]]</span>
# Epidemiology
Peak incidence is between <span style="background:rgba(240, 200, 0, 0.2)">50 and 74 years of age.</span>

---
# Etiology


---
# Pathophysiology
Genetic mutations → <span style="background:rgba(240, 200, 0, 0.2)">hyperplasia of atypical megakaryocytes</span> → ↑ TGF-β → ↑ fibroblast activity → bone marrow obliteration due to fibrosis → displacement of hematopoietic stem cells → extramedullary hematopoiesis

---
# Clinical features
- Constitutional symptoms
- [[USMLE/Blood/Anemia\|Anemia]]
- <span style="background:rgba(240, 200, 0, 0.2)">Symptomatic [[USMLE/Blood/Splenomegaly\|splenomegaly]]</span>
- Thromboembolic events 
	- Due to thrombocytosis and leukocytosis in the prefibrotic proliferative phase
- Petechial bleeding 
- Increased infections 




---
# Diagnostics
- CBC
	- Classic presentation: [[USMLE/Blood/Anemia\|anemia]], thrombocytosis, and leukocytosis
	- Patients may additionally present with:
		- Thrombocytopenia (33%) 
		- [[USMLE/Blood/Pancytopenia\|Pancytopenia]] (10%)
- ↑ [[USMLE/Blood/Leukocyte alkaline phosphatase\|Leukocyte alkaline phosphatase]], LDH
- Peripheral blood smear: dacrocytes (teardrop cells)
- JAK2 mutation
- Bone marrow studies
	- Aspiration often fails (dry tap) because of severe marrow fibrosis.

---
# Differential diagnostics
| Feature              | Myelofibrosis (MF)                                                             | Aplastic Anemia (AA)                                                       |
| :------------------- | :----------------------------------------------------------------------------- | :------------------------------------------------------------------------- |
| **Pathophysiology**  | Myeloproliferative Neoplasm (MPN) → ↑ Cytokines → Reactive BM **fibrosis**     | Autoimmune destruction of hematopoietic stem cells (HSCs) → BM **failure** |
| **BM Biopsy**        | **Hypercellular** → **Fibrotic**. "Dry tap" common.                            | Markedly **hypocellular** / empty; replaced by fat.                        |
| **Splenomegaly**     | **Massive** (due to Extramedullary Hematopoiesis - EMH). **Hallmark finding**. | **Absent**.                                                                |
| **Peripheral Smear** | **Leukoerythroblastosis** & **Dacrocytes** (teardrop RBCs).                    | Pancytopenia with **normal morphology**.                                   |
| **Genetics**         | **JAK2**, CALR, MPL mutations (~90%).                                          | No specific mutations; idiopathic/autoimmune.                              |
| **Key Sx**           | Constitutional "B" symptoms, early satiety, bone pain.                         | Sx of pancytopenia: fatigue, infections, bleeding.                         |
| **Age**              | Typically >50 y/o.                                                             | Bimodal: young adults & elderly.                                           |
>[!tip] Myelofibrosis vs [[USMLE/Blood/Aplastic anemia\|Aplastic anemia]]
>- Myelofibrosis: <span style="background:rgba(240, 200, 0, 0.2)">[[USMLE/Blood/Splenomegaly\|splenomegaly]]</span>
>	- <span style="background:rgba(240, 200, 0, 0.2)">Evidence of extra medullary hematopoesis</span>
>- [[USMLE/Blood/Aplastic anemia\|Aplastic anemia]]: no
>- Explanation: In myeloproliferative disorders like myelofibrosis, niche in marrow is disturbed by slow fibrosis of marrow so <span style="background:rgba(240, 200, 0, 0.2)">stem cells migrate and extra medullary haematopoiesis occurs</span>. <span style="background:rgba(240, 200, 0, 0.2)">But in aplastic anemia</span> (whether primary or secondary to drugs etc) <span style="background:rgba(240, 200, 0, 0.2)">stem cells themselves are destroyed or affected so haematopoiesis not possible anywhere.</span> So we don't get hepatosplenomegaly and other evidences of extramedullary haematopoiesis.
# Treatment


---
